In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator : Correlation with physico-chemical properties and oral activity

The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. Caco-2 epithelial monolayer and in situ ra...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical research Vol. 16; no. 3; pp. 434 - 440
Main Authors LOWTHER, N, FOX, R, FALLER, B, NICK, H, YI JIN, SERGEJEW, T, HIRSCHBERG, Y, OBERLE, R, DONNELLY, H
Format Journal Article
LanguageEnglish
Published New York, NY Springer 01.03.1999
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. Caco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures. Caco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals. Caco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate.
AbstractList The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. Caco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures. Caco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals. Caco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate.
The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. Caco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures. Caco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals. Caco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate.
PURPOSEThe in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is described. The predictive power of these data in assessing intestinal absorption in man is described. METHODSCaco-2 epithelial monolayer and in situ rat jejunum perfusion intestinal permeability models were utilized. In vivo iron excretion and preliminary animal pharmacokinetic experiments were described. Ionization constants and octanol/aqueous partition coefficients were measured potentiometrically. Solubilities and intrinsic dissolution rates were determined using standard procedures. RESULTSCaco-2 cell (Papp approximately 0.25 x 10(-6) cm x s(-1)) and rat jejunum (Pw approximately 0.4) permeabilities of CGP 65015 were determined. The log D(pH 7.4) of CGP 65015 was 0.58 and its aqueous solubility was < 0.5 mg x ml(-1) (pH 3-9). The intrinsic dissolution rate of CGP 65015 in USP simulated intestinal fluid was 0.012 mg x min(-1) x cm(-2). CGP 65015 promotes iron excretion effectively and dose dependently in animals. CONCLUSIONSCaco-2 and rat intestinal permeabilities predict incomplete oral absorption of CGP 65015 in man. Preliminary rat pharmacokinetics support this. Physico-chemical data are, also, in line and suggest that CGP 65015 may, in addition, be solubility/dissolution rate limited in vivo. Nevertheless, early animal pharmacological data demonstrate that CGP 65015 is a viable oral iron chelator candidate.
Author DONNELLY, H
OBERLE, R
FALLER, B
HIRSCHBERG, Y
LOWTHER, N
FOX, R
NICK, H
SERGEJEW, T
YI JIN
Author_xml – sequence: 1
  givenname: N
  surname: LOWTHER
  fullname: LOWTHER, N
  organization: Pharmaceutical and Analytical Development, Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom
– sequence: 2
  givenname: R
  surname: FOX
  fullname: FOX, R
  organization: Pharmaceutical and Analytical Development, Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, United Kingdom
– sequence: 3
  givenname: B
  surname: FALLER
  fullname: FALLER, B
  organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland
– sequence: 4
  givenname: H
  surname: NICK
  fullname: NICK, H
  organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland
– sequence: 5
  surname: YI JIN
  fullname: YI JIN
  organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland
– sequence: 6
  givenname: T
  surname: SERGEJEW
  fullname: SERGEJEW, T
  organization: Iron Chelation Research, Novartis Pharma AG, 4002 Basel, Switzerland
– sequence: 7
  givenname: Y
  surname: HIRSCHBERG
  fullname: HIRSCHBERG, Y
  organization: Bioanalytics and Pharmacokinetics, Novartis Pharmaceuticals Corporation, Summit, New Jersey, United States
– sequence: 8
  givenname: R
  surname: OBERLE
  fullname: OBERLE, R
  organization: Bioanalytics and Pharmacokinetics, Novartis Pharmaceuticals Corporation, Summit, New Jersey, United States
– sequence: 9
  givenname: H
  surname: DONNELLY
  fullname: DONNELLY, H
  organization: Globepharm Ltd, P.O. Box 89C, Esher, Surrey KT10 9ND, United Kingdom
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1738283$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10213376$$D View this record in MEDLINE/PubMed
BookMark eNpdkE1rFTEUhoNU7G117U6CiF2NniQzmUx35eJHoeBGwd2QZM54U2aSMclU59_4U03rFcHV4cDznvPwnpETHzwS8pzBGwZcvL26ZMCUUhKgYUI-IjvWtKLqoP56QnbQ8rpSbc1OyVlKtwCgWFc_Iacly4Ro5Y78uvb0zuUYqPYDdZ4ml1e6YJxRGze5vNEwUk0vEtpQiG_oMersgr-gh22I4ee2bNEN7l6Mhqgn6mLw1B5w0jlEekn3Icb7pWToD5cPdDlsydlQFWZ2tiSWGMrH7DA9WDxc0Ta7IrY9JY9HPSV8dpzn5Mv7d5_3H6ubTx-u91c31cKlyJXgTDHeSWOVqREFNi2gFNYAGwDHWsLARhBSKNtIY4yQgMjBMADejDUX5-T1n7tF5vuKKfezSxanSXsMa-pl10LLlCjgy__A27BGX9x6zrnsFIe6QC-O0GpmHPolulnHrf9bfAFeHQGdSgVj1N669I9rheLl2W8gh5XI
CODEN PHREEB
ContentType Journal Article
Copyright 1999 INIST-CNRS
Copyright Kluwer Academic Publishers Mar 1999
Copyright_xml – notice: 1999 INIST-CNRS
– notice: Copyright Kluwer Academic Publishers Mar 1999
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TK
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1023/A:1018886005136
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Neurosciences Abstracts
ProQuest_Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Nursing & Allied Health Premium
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
Neurosciences Abstracts
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest One Academic Eastern Edition
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1573-904X
EndPage 440
ExternalDocumentID 520263981
10213376
1738283
Genre Journal Article
News
GroupedDBID ---
-4W
-56
-5G
-BR
-EM
-Y2
-~C
.86
.VR
06C
06D
0R~
0VY
123
199
1N0
1SB
2.D
203
28-
29O
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
3SX
3V.
4.4
406
408
409
40D
40E
53G
5QI
5VS
67N
67Z
6NX
78A
7RV
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
8W4
95-
95.
95~
96X
AAAVM
AABHQ
AABYN
AAFGU
AAHNG
AAIAL
AAJKR
AANXM
AANZL
AAPBV
AARHV
AARTL
AATVU
AAUYE
AAWCG
AAYIU
AAYOK
AAYQN
AAYTO
ABBBX
ABBXA
ABDZT
ABECU
ABFGW
ABFLS
ABFTV
ABHLI
ABHQN
ABIPD
ABJOX
ABKAS
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABPTK
ABQBU
ABSXP
ABTEG
ABTHY
ABTMW
ABULA
ABUWG
ABXPI
ACBMV
ACBRV
ACBXY
ACBYP
ACGFS
ACHSB
ACHXU
ACIGE
ACIPQ
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACTTH
ACVWB
ACWMK
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADMDM
ADOAH
ADRFC
ADTIX
ADURQ
ADYFF
ADYPR
ADZKW
AEBTG
AEFIE
AEFTE
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESTI
AETLH
AEVTX
AEXYK
AFDYV
AFEXP
AFGCZ
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGBP
AGGDS
AGJBK
AGMZJ
AGQMX
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AIMYW
AITGF
AJBLW
AJDOV
AJRNO
AJZVZ
AKMHD
AKQUC
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMYLF
AMYQR
AOSHJ
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBAFP
BBWZM
BDATZ
BENPR
BGNMA
BKEYQ
BPHCQ
BVXVI
CAG
COF
CS3
CSCUP
DL5
DNIVK
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
EN4
EPAXT
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
H13
HF~
HG5
HG6
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IAO
IHE
IJ-
IMOTQ
INH
IPNFZ
IQODW
ITM
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
KSO
L7B
LAK
LLZTM
LSO
M1P
M4Y
MA-
MK0
N2Q
N95
N9A
NAPCQ
NB0
NDZJH
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
PF0
PQEST
PQQKQ
PQUKI
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZC
RZE
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SBY
SCLPG
SDH
SHX
SISQX
SJYHP
SNE
SNX
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TEORI
TSG
TSK
TSV
TUC
U2A
U9L
UG4
UKHRP
UNUBA
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WH7
WJK
WK6
WK8
WOW
YCJ
YLTOR
Z45
Z5O
Z7S
Z7U
Z7V
Z7W
Z7X
Z81
Z82
Z83
Z84
Z87
Z88
Z8N
Z8O
Z8P
Z8Q
Z8R
Z8V
Z8W
Z91
Z92
ZGI
ZMTXR
ZOVNA
~KM
AACDK
AAEOY
AAJBT
AAQLM
AASML
AATNV
AAYZH
ABAKF
ABJNI
ABTKH
ABWNU
ACAOD
ACDTI
ACZOJ
ADTPH
AEFQL
AEMSY
AESKC
AEVLU
AFBBN
AGQEE
AGRTI
AIGIU
ALIPV
AMXSW
AOCGG
CCPQU
CGR
CUY
CVF
DDRTE
DPUIP
ECM
EIF
HMCUK
IKXTQ
IWAJR
NPM
NPVJJ
SNPRN
SOHCF
7TK
7XB
8FK
K9.
PRINS
7X8
ID FETCH-LOGICAL-p263t-32181296bc8b4ee3e570e63cb01d0ef460d1f03638c56bbb360ee20b10025f423
IEDL.DBID BENPR
ISSN 0724-8741
IngestDate Fri Oct 25 08:26:48 EDT 2024
Thu Oct 10 18:47:48 EDT 2024
Wed Oct 16 00:50:10 EDT 2024
Fri Nov 25 06:01:31 EST 2022
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Human
Rat
Digestive system
Biological transport
Rodentia
Gut
Solubility
Oral administration
Lipophily
Iron
Bioavailability
Permeability
In vitro
In vivo
Vertebrata
Mammalia
Absorption
Animal
Established cell line
Chelating agent
Pharmacokinetics
Tumor cell
Physicochemical properties
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p263t-32181296bc8b4ee3e570e63cb01d0ef460d1f03638c56bbb360ee20b10025f423
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 10213376
PQID 222698204
PQPubID 37334
PageCount 7
ParticipantIDs proquest_miscellaneous_69707183
proquest_journals_222698204
pubmed_primary_10213376
pascalfrancis_primary_1738283
PublicationCentury 1900
PublicationDate 1999-03-01
PublicationDateYYYYMMDD 1999-03-01
PublicationDate_xml – month: 03
  year: 1999
  text: 1999-03-01
  day: 01
PublicationDecade 1990
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
– name: New York
PublicationTitle Pharmaceutical research
PublicationTitleAlternate Pharm Res
PublicationYear 1999
Publisher Springer
Springer Nature B.V
Publisher_xml – name: Springer
– name: Springer Nature B.V
SSID ssj0008194
Score 1.6917957
Snippet The in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator, is...
PURPOSEThe in vitro and in situ transport of CGP 65015 ((+)-3-hydroxy-1-(2-hydroxyethyl)-2-hydroxyphenyl-methyl-1H-pyridin-4-on e), a novel oral iron chelator,...
SourceID proquest
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 434
SubjectTerms Administration, Oral
Animals
Biological and medical sciences
Caco-2 Cells
Callithrix
Carbon Radioisotopes
General and cellular metabolism. Vitamins
Humans
In Vitro Techniques
Intestinal Absorption
Iron Chelating Agents - chemistry
Iron Chelating Agents - pharmacokinetics
Jejunum - metabolism
Male
Mannitol - metabolism
Medical sciences
Perfusion
Permeability
Pharmacology. Drug treatments
Pyridines - chemistry
Pyridines - pharmacokinetics
Rats
Rats, Inbred F344
Title In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator : Correlation with physico-chemical properties and oral activity
URI https://www.ncbi.nlm.nih.gov/pubmed/10213376
https://www.proquest.com/docview/222698204
https://search.proquest.com/docview/69707183
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Nb9QwELXo9oKEEN8spWUOqL00Iokde8MFlVWrLYcS0RbtbWXHjthLEpLsIb-Gv8pMnN0VSHCMooysjD3zxn5-w9h7oYpU20FP24SBUCIJtMt1IIzQDsMhqekQ2-JGLu7Fl2WyHLk57Uir3MbEIVDbKqc98g-Yx2SK6Up8qn8G1DSKDlfHDhoH7DDGQiGcsMPPlzfZt10oxnQ36EepWOCyF9Ff2j4Rln-SpiUJND-qdYu_pfD9LP4NOIfEc_WEPR4RI1x4Fz9lD1z5jJ1mXnK6P4e7_Q2q9hxOIduLUffP2a_rEr6vu6YCXVrAh9t1t4EM47HzCt09VAVoOLulytiCl6Emb53BordEcqn7Zo0ZriodfG1wJNdNVcL8B7HoquYjzKm_h2fUAe3qwkAqzatgq0UAGW34N6TcOgxiMHKR-7YVL9j91eXdfBGMTRmCOpa8C_iACVJp8pkRznGXqNBJnpswsqErhAxtVNDp8CxPpDGGy9C5ODQk9ZoUCN5esgmN-DWDQvAZwh9jVKSF4oVOotwKK12Smlg7O2XHf_hkVXsBjlWkOBaKfMqOtj5ajSuvXe3myZS9273FJUPnILp01aZdyVQhsKLvX3nH7g0j4uEYct_81_IRe-jFG4iJ9pZNumbjjhGadOaEHailOhmn4W-M3eZd
link.rule.ids 315,783,787,12068,21400,27936,27937,31731,31732,33756,33757,43322,43817,74079,74636
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Pb9MwFLZgHEBCiN90Y-wd0HZZRFI7dsMFTRVTC2NUWod6i-zYEb0kWZIe8tfwr_JenLYCCY5VVMvKs9_7nv3l-xh7L1SeaNvraZswEErEgXaZDoQR2mE6JDUdYltcy9mt-LKKVwM3pxlolduc2CdqW2Z0Rv4B65hMsFyJT9VdQKZRdLk6OGjcZw9IhosMDNRq129RsevVo9RY4KYX0V_KPhE2f5IWJckzP650gy8l924W_4abfdm5fMqeDHgRLnyAn7F7rnjOThdecLo7h-X--6nmHE5hsZei7l6wX_MCfqzbugRdWMAfN-t2AwvMxs7rc3dQ5qDh7Ib6YgtehJpidQazzhLFperqNda3snDwvcaZzOuygOlP4tCV9UeYkruH59MBnelCTynNymCrRAALOu6vSbe1n0Q_yEXmTStestvLz8vpLBgsGYJqLHkb8B4RJNJkEyOc4y5WoZM8M2FkQ5cLGdoop7vhSRZLYwyXoXPj0JDQa5wjdHvFDmjGbxjkgk8Q_BijIi0Uz3UcZVZY6eLEjLWzI3b8R0zSystvpJHi2CbyETvaxigd9l2T7lbJiJ3snuKGoVsQXbhy06QyUQir6P-vfWD3AyPe4ZhwD_878gl7OFt-u0qv5tdfj9gjL-NAnLS37KCtN-4YQUpr3vVL8Tc84OcB
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZgSAgJIX7TjbF7QNvLoiW1Yze8oKlQtYBGpW2ob5EdO6IvSZakD_lr-Fe5i9NWIMFjFMWycue77-zP3zH2Xqg80bbX0zZhIJSIA-0yHQgjtMNwSGo6xLa4kvNb8WUVrwZJoWagVW5jYh-obZnRHvkF5jGZYLoSF_nAilh-mn2s7gJqIEUHrUM3jfvsgcIihRxcrXa1FyW-XklKjQUGABH9pfITYSEoyUFJqvlxpRv8QbnvbPFv6NmnoNlT9mTAjnDpjf2M3XPFc3a69OLT3Tnc7O9SNedwCsu9LHX3gv1aFPBj3dYl6MICPlyv2w0sMTI7r9XdQZmDhrNrqpEteEFqstsZzDtLdJeqq9eY68rCwfcaZ7KoywKmP4lPV9YfYEqdPjy3Dmh_F3p6aVYGW1UCWNLWf00arv0k-kEuM9_A4iW7nX2-mc6DoT1DUI0lbwPeo4NEmmxihHPcxSp0kmcmjGzociFDG-V0TjzJYmmM4TJ0bhwaEn2Nc4Rxr9gBzfgNg1zwCQIhY1SkheK5jqPMCitdnJixdnbEjv-wSVp5KY40UhxLRj5iR1sbpcMabNKdx4zYye4tLh46EdGFKzdNKhOFEIu-f-0Nux8YsQ_H4Hv435FP2EP0wvTb4urrEXvkFR2InvaWHbT1xh0jXmnNu94TfwP6pOs_
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+vitro+and+in+situ+permeability+of+a+%27second+generation%27+hydroxypyridinone+oral+iron+chelator%3A+correlation+with+physico-chemical+properties+and+oral+activity&rft.jtitle=Pharmaceutical+research&rft.au=Lowther%2C+N&rft.au=Fox%2C+R&rft.au=Faller%2C+B&rft.au=Nick%2C+H&rft.date=1999-03-01&rft.issn=0724-8741&rft.volume=16&rft.issue=3&rft.spage=434&rft_id=info:doi/10.1023%2FA%3A1018886005136&rft_id=info%3Apmid%2F10213376&rft.externalDocID=10213376
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0724-8741&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0724-8741&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0724-8741&client=summon